Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

9P - Lung cancer mutational state assessed by NGS in a Portuguese Center


24 Mar 2021


e-Poster Display Session




Journal of Thoracic Oncology (2021) 16 (suppl_4): S699-S703.


D. MAGALHÃES1, M. Vilaça2, É. Cipriano2, A. Tavares2, D. Silva2, L. Cirnes3, H. Magalhães2, F. Estevinho2

Author affiliations

  • 1 ULS Matosinhos - Hospital Pedro Hispano EPE - SNS, Senhora da Hora/PT
  • 2 ULS Matosinhos - Hospital Pedro Hispano EPE - SNS, 4464-513 - Senhora da Hora/PT
  • 3 Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), 4200-135 - Porto/PT

Abstract 9P


In advanced non-squamous non-small cell lung cancer (NSCLC), and other selected NSCLC patients molecular testing is crucial to detect oncogenic driver mutations and to direct treatment regarding the molecular profile. Next-generation sequencing (NGS) allows accurate and efficient multiple genes and mutation analyses. This technique offers an extensive molecular tumor characterization in a cost-effective and timely manner. Our aim was to evaluate the NGS mutational profile and to correlate the results with clinicopathological characteristics and PD-L1 expression in patients with NSCLC.


Retrospective study of the NGS analysis, carried out in patients (pts) with NSCLC between January 2017 and December 2020 in our oncological center in Portugal. Clinicopathological characteristics were accessed by review of medical records. A descriptive analysis was performed, and Qui square was used to compare categorical variables. P-value reported was two-sided, and tests were conducted at the 0.05 significance level, SPSS®20.


A total of 299 pts with NSCLC were analyzed, 293 had a valid test. The median age was 69 years. 71% (n = 211) were males, 21% (n = 62) were non-smokers and 33% (n = 99) were smokers. 65% (n = 190) of the pts had at least one mutation. 73 pts (38%) had a mutation with a therapeutic target approved by EMA. KRAS was the most found mutation (31%), followed by EGFR (14%) and ALK (5%). EGFR, ALK, ROS1 and RET were more prevalent in females (p < 0.05), KRAS was more common in males. EGFR and RET were more common in pts younger than 50 years old (p < 0.05). EGFR was most found in non-smokers, KRAS was the most prevalent in smokers and former smokers (p < 0.05). Regarding tumor PD-L1 expression, BRAF and MET variants were more common in PD-L1 ≥50% (p < 0.05), while EGFR was more common in PD-L1 <50% (p < 0.05).


KRAS and EGFR prevalence were in accordance with the previous reported in Caucasian population. Some mutations correlate with clinic-pathological characteristics as sex, smoking status, and PD-L1 expression. Our study provides results from broad molecular profiling of Portuguese NSCLC pts treated in one hospital. In the future, multicentre data analysis will be presented.

Legal entity responsible for the study

The authors.


Has not received any funding.


F. Estevinho: Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings